Rituximab Combined With ESHAP in Patients With Relapse or Refractory Diffuse Large B Cell Lymphoma (DLBCL)
Status:
Completed
Trial end date:
2010-12-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the efficacy and toxicity of Rituximab combined with
ESHAP (etoposide, methylprednisolone, cytarabine, and cisplatin) in the patients with diffuse
large B cell lymphoma (DLBCL).